🚀 VC round data is live in beta, check it out!
Cabaletta Bio Valuation Multiples
Discover revenue and EBITDA valuation multiples for Cabaletta Bio and similar public comparables like Candel Therapeutics, Rezolute, Racura Oncology, Greenwich LifeSciences and more.
Cabaletta Bio Overview
About Cabaletta Bio
Cabaletta Bio Inc is a clinical-stage biotechnology company focused on the discovery and development of engineered T cell therapies and exploring their potential to provide a deep and durable, perhaps curative, treatment for patients with B cell-mediated autoimmune diseases. Its proprietary technology utilizes Chimeric AutoAntibody Receptor, or CAART cells, that are designed to selectively bind and eliminate only specific B cells that produce disease-causing autoantibodies, or pathogenic B cells, while sparing normal B cells. Its CABA platform encompasses two strategies: CARTA (chimeric antigen receptor T cells for autoimmunity) and CAART (chimeric autoantibody T cells) that have the potential to be applied across a broad range of autoimmune diseases.
Founded
2017
HQ
Employees
164
Website
Sectors
Financials (LTM)
EV
$246M
Cabaletta Bio Financials
Cabaletta Bio reported last 12-month revenue of — and negative EBITDA of ($176M).
In the same LTM period, Cabaletta Bio generated — in gross profit, ($176M) in EBITDA losses, and had net loss of ($174M).
Revenue (LTM)
Cabaletta Bio P&L
In the most recent fiscal year, Cabaletta Bio reported revenue of — and EBITDA of ($164M).
Cabaletta Bio expects next 12-month revenue of XXX and NTM EBITDA of XXX
| LTM | NTM | Last FY | FY 2026 | FY 2027 | FY 2028 | |
|---|---|---|---|---|---|---|
| EBITDA | ($176M) | XXX | ($164M) | XXX | XXX | XXX |
| Net Profit | ($174M) | XXX | ($168M) | XXX | XXX | XXX |
Financial data powered by Morningstar, Inc.
Cabaletta Bio Stock Performance
Cabaletta Bio has current market cap of $353M, and enterprise value of $246M.
Market Cap Evolution
Cabaletta Bio's stock price is $3.17.
| EV | Market Cap | Price 1D | Price 1M | Price 3M | Price 12M | EPS |
|---|---|---|---|---|---|---|
| $246M | $353M | 2.3% | XXX | XXX | XXX | $-1.51 |
Benchmark Trading Valuation Multiples by Industry
Sign up to access valuation multiples like growth-adjusted P/E, Rule of 40, next 12-month EV/Revenue, EBITDA multiples by industry, consensus analyst estimates and many more.
Start Free TrialCabaletta Bio Valuation Multiples
Cabaletta Bio trades at (1.4x) EV/EBITDA.
EV / Revenue (LTM)
Cabaletta Bio Financial Valuation Multiples
As of April 11, 2026, Cabaletta Bio has market cap of $353M and EV of $246M.
Equity research analysts estimate Cabaletta Bio's 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX
Cabaletta Bio has a P/E ratio of (2.0x).
| LTM | NTM | Last FY | FY 2026 | FY 2027 | FY 2028 | |
|---|---|---|---|---|---|---|
| Market cap (current) | $353M | XXX | $353M | XXX | XXX | XXX |
| EV (current) | $246M | XXX | $246M | XXX | XXX | XXX |
| EV/EBITDA | (1.4x) | XXX | (1.5x) | XXX | XXX | XXX |
| EV/EBIT | (1.4x) | XXX | (1.4x) | XXX | XXX | XXX |
| P/E | (2.0x) | XXX | (2.1x) | XXX | XXX | XXX |
| EV/FCF | — | XXX | (1.9x) | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Verified Cabaletta Bio Valuation Multiples
Access all public comps and forward-looking valuation multiples like EV/Revenue in 2027, based on consensus analyst estimates. Powered by FactSet and Morningstar.
Cabaletta Bio Margins & Growth Rates
Cabaletta Bio's revenue in the last fiscal year grew by —.
Cabaletta Bio's revenue per employee in the last FY averaged $0.0M, while opex per employee averaged $1.1M for the same period.
Cabaletta Bio Operational Valuation Multiples
| LTM | NTM | Last FY | FY 2026 | FY 2027 | FY 2028 | |
|---|---|---|---|---|---|---|
| EBITDA Growth | 11% | XXX | 15% | XXX | XXX | XXX |
| Revenue per Employee | — | XXX | $0.0M | XXX | XXX | XXX |
| Opex per Employee | — | XXX | $1.1M | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Cabaletta Bio Public Comps
See public comps and valuation multiples for other Biopharmaceuticals comps.
| EV/Revenue | EV/EBITDA | |||||
|---|---|---|---|---|---|---|
| LTM | 2026E | 2027E | LTM | 2026E | 2027E | |
| Candel Therapeutics | XXX | XXX | XXX | XXX | XXX | XXX |
| Rezolute | XXX | XXX | XXX | XXX | XXX | XXX |
| Racura Oncology | XXX | XXX | XXX | XXX | XXX | XXX |
| Greenwich LifeSciences | XXX | XXX | XXX | XXX | XXX | XXX |
| Bicycle Therapeutics | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc.
Cabaletta Bio M&A Activity
Cabaletta Bio acquired XXX companies to date.
Last acquisition by Cabaletta Bio was on XXXXXXXX, XXXXX. Cabaletta Bio acquired XXXXXXXX for XXX (EV/Revenue multiple of XXX).
Latest Acquisitions by Cabaletta Bio
| Acquired Company | Valuation | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
Get Verified M&A Valuation Multiples
Sign up to see revenue and EBITDA valuation multiples for 150K+ M&A deals.
Start Free TrialCabaletta Bio Investment Activity
Cabaletta Bio invested in XXX companies to date.
Cabaletta Bio made its latest investment on XXXXXXXX, XXXXX. Cabaletta Bio invested in XXXXXXXX for XXX (EV/Revenue multiple of XXX).
Latest Investments by Cabaletta Bio
| Company | Valuation | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
Benchmark 350K+ Funding Rounds and Disclosed VC Valuation Multiples
Sign up to see data on 350K+ funding rounds and disclosed revenue and EBITDA valuation multiples, from seed, through growth stage, to pre-IPO.
Start Free TrialAbout Cabaletta Bio
| When was Cabaletta Bio founded? | Cabaletta Bio was founded in 2017. |
| Where is Cabaletta Bio headquartered? | Cabaletta Bio is headquartered in United States. |
| How many employees does Cabaletta Bio have? | As of today, Cabaletta Bio has over 164 employees. |
| Who is the CEO of Cabaletta Bio? | Cabaletta Bio's CEO is Steven Nichtberger. |
| Is Cabaletta Bio publicly listed? | Yes, Cabaletta Bio is a public company listed on Nasdaq. |
| What is the stock symbol of Cabaletta Bio? | Cabaletta Bio trades under CABA ticker. |
| When did Cabaletta Bio go public? | Cabaletta Bio went public in 2019. |
| Who are competitors of Cabaletta Bio? | Cabaletta Bio main competitors are Candel Therapeutics, Rezolute, Racura Oncology, Greenwich LifeSciences. |
| What is the current market cap of Cabaletta Bio? | Cabaletta Bio's current market cap is $353M. |
| Is Cabaletta Bio profitable? | No, Cabaletta Bio is not profitable. |
| What is the current EBITDA of Cabaletta Bio? | Cabaletta Bio has negative EBITDA and is not profitable. |
| What is the current EV/EBITDA multiple of Cabaletta Bio? | Current EBITDA multiple of Cabaletta Bio is (1.4x). |
Start Your
Free Trial Today
Try Multiples for free for 3 days. Got questions or need a demo? Schedule a call with us below.